Merit Medical Launches TEMNO Elite™ Soft Tissue Biopsy System

0

[ad_1]

Advanced device delivers 72% larger specimens, simplifies tissue recovery and improves patient safety

/EIN News/ — SOUTH JORDAN, Utah, Sept. 27, 2022 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), one of the world’s leading manufacturers and distributors of health technologies, announced today the commercial release in the United States of the TEMNO Elite™ Soft Tissue Biopsy System, the latest addition to Merit’s comprehensive line of biopsy devices.

Indicated for use in a variety of soft tissue locations, such as the liver, lungs, lymph nodes, kidneys and other suspected soft tissue lesions, the single-use device is the result of Merit’s continued commitment towards the advancement of biopsy procedures and complements a broader portfolio, which includes the TEMNO™, Achieve® and Tru-Cut® device families.

Biopsies are regularly done to remove and examine tissue to help diagnose the disease. Adequate sample size and quality are paramount for accurate diagnosis and treatment. Designed to retrieve superior samples, TEMNO Elite’s Total Core™ biopsy technology achieves 72% larger samples than competing semi-automatic side notch devices.1

To provide clinicians with full procedural control, the device’s premier Sample Assist™ feature simplifies tissue removal, allowing clinicians to retrieve complete samples with the flick of a button. An optional valved coaxial introducer improves patient safety by reducing the risk of air entry and fluid leakage, especially important during lung biopsy.2

“The sample quality from the TEMNO Elite is excellent,” said Stuart Aronson, MD, diagnostic radiology specialist at Texas Health Harris Methodist Hospital in Fort Worth, TX. “The hearts are significantly and consistently larger than other devices. The valved coaxial introducer reduces procedural steps and blood leakage and helps reduce the risk of pneumothorax and gas embolism.

Learn more about the TEMNO Elite Biopsy System.

“Merit is committed to helping physicians provide the best possible care to their patients, and that includes the critical step of an accurate diagnosis,” said Fred P. Lampropoulos, president and CEO of Merit Medical. “The TEMNO Elite is the latest innovation in our soft tissue biopsy device portfolio, and it highlights Merit’s ability to understand clinician and patient needs and to innovate and deliver technologies that advance care.” to patients. We are pleased to continue our progress in improving diagnostic accuracy in pathology laboratories across the country. »

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, intensive care and endoscopy. Merit serves hospital customers worldwide with a domestic and international sales force and clinical support team totaling more than 500 people. Merit employs approximately 6,500 people worldwide.

TRADEMARKS Unless otherwise noted, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.

CONTACTS

PR/Media Inquiries
Sarah Comstock
medical merit
+1-801-432-2864 | [email protected]

INVESTOR REQUESTS
Mike Piccinino, CFA, IRC
Westwicke – ICR
+1-443-213-0509 | [email protected]

REFERENCES

  1. Internal test with 18G. Data on file. Marketing claims for the TEMNO Elite device (ECN147270).
  2. Internal testing. Data on file. Validated with Centesis Valved One-Step™ Catheter data. See product brochure (401273001/C, ECN99826).

main logo

[ad_2]
Source link

Share.

Comments are closed.